Patents by Inventor Zhe Wan

Zhe Wan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEURAL NETWORK SYSTEM WITH NEURONS INCLUDING CHARGE-TRAP TRANSISTORS AND NEURAL INTEGRATORS AND METHODS THEREFOR
    Publication number: 20240028884
    Abstract: Present implementations can include a system with a transistor array including a plurality of charge-trap transistors, the charge-trap transistors being operatively coupled with corresponding input nodes, and a neural integrator including a first integrator node and a second integrator node operatively coupled with the transistor array, and generating an output corresponding to a neuron of a neural network system.
    Type: Application
    Filed: October 4, 2021
    Publication date: January 25, 2024
    Applicant: The Regents of the University of California
    Inventors: Steven L. MORAN, Subramanian S. IYER, Zhe WAN, Sudhakar PAMARTI
  • Oligomer extended insulin-Fc conjugates
    Patent number: 11471537
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 18, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra
  • OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE
    Publication number: 20210393745
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to a novel Fc fragment, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 23, 2021
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Zhaosheng Lin, Yuanyuan Zhang, Zhe Wan
  • Oligomer Extended Insulin-FC Conjugates
    Publication number: 20200261595
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 20, 2020
    Applicant: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra